Author name: Mike M.

apple-hits-“all-time-high”-smartphone-market-share,-takes-#1-spot-for-2023

Apple hits “all-time high” smartphone market share, takes #1 spot for 2023

Eww Android phones, who would want those? —

Apple beat all the Android OEMs while selling dramatically more expensive phones.

The Apple logo takes corporeal form outside an Apple store.

Market research firm IDC has released some stunning smartphone market share numbers for 2023. The number one smartphone OEM is now Apple. The IDC says Apple hit an “all-time high market share” number for 2023 and that Apple has “the number 1 spot annually for the first time ever.” The analyst group says this represents “a sort of shifting of power” in the smartphone market.

That all-time high market share puts Apple at 20.1 percent for 2023, a 3.7 percent growth over 2022. Nearly everyone on Team Android is way down, with Samsung now in second place after losing 13.6 percent in 2023 for 19.4 percent market share on the year. Chinese firm Xiaomi is down 4.7 percent for 12.5 percent market share, and Oppo (the parent company of OnePlus) dropped 9.9 percent and is fourth, with 8.8 percent of the market. Next up is “Transsion,” a company that is definitely not a household name but is big in emerging markets like Africa. Transsion is a big winner, with 30 percent growth from 2022 to 2023. With 8.1 percent market share, it takes the fifth spot.

The IDC's market share charts for 2023.

Enlarge / The IDC’s market share charts for 2023.

Apple is usually not first in sales because the average iPhone purchase is much more expensive than an average Android phone. Samsung’s cheapest phones can be had for about $50, and while you can get a wildly expensive foldable that costs a lot more than an iPhone, Samsung’s bestselling models are often the midrange “A” series, which are in the $200–$450 range. Other Android manufacturers are in the same boat, with low-volume halo products and high-volume cheap devices.

According to Omdia’s top-10 model sales list for 2023, Apple’s bestselling phone—and the bestselling phone model in the world—was the $1,100 iPhone 14 Pro Max. The world’s second bestselling phone is the $1,000 iPhone 14 Pro. Third is the iPhone 14, which cost $800 for most of 2023. Apple’s cheapest phone is the iPhone SE at $429, but that model doesn’t sell well. The point is that Android manufacturers usually win these market share charts by selling cheap and midrange phones, but Apple was able to take the top spot while existing only in the mid-to-premium phone space. The industry lingo for this is “average sell price” (ASP), and for Q2 2023, the IDC has the average Android phone at $250, while the average iPhone costs $949.

In 2020, Apple was fourth in market share behind Samsung, Huawei, and Xiaomi, which made sense given Apple’s more expensive product line. In 2023, Apple beat all these Android OEMs while selling dramatically more expensive products. The IDC’s Nabila Popal wraps up the numbers by saying, “Apple’s ongoing success and resilience is in large part due to the increasing trend of premium devices, which now represent over 20% of the market, fueled by aggressive trade-in offers and interest-free financing plans.”

Apple hits “all-time high” smartphone market share, takes #1 spot for 2023 Read More »

what-do-threads,-mastodon,-and-hospital-records-have-in-common?

What do Threads, Mastodon, and hospital records have in common?

A medical technician looks at a scan on a computer monitor.

It’s taken a while, but social media platforms now know that people prefer their information kept away from corporate eyes and malevolent algorithms. That’s why the newest generation of social media sites like Threads, Mastodon, and Bluesky boast of being part of the “fediverse.” Here, user data is hosted on independent servers rather than one corporate silo. Platforms then use common standards to share information when needed. If one server starts to host too many harmful accounts, other servers can choose to block it.

They’re not the only ones embracing this approach. Medical researchers think a similar strategy could help them train machine learning to spot disease trends in patients. Putting their AI algorithms on special servers within hospitals for “federated learning” could keep privacy standards high while letting researchers unravel new ways to detect and treat diseases.

“The use of AI is just exploding in all facets of life,” said Ronald M. Summers of the National Institutes of Health Clinical Center in Maryland, who uses the method in his radiology research. “There’s a lot of people interested in using federated learning for a variety of different data analysis applications.”

How does it work?

Until now, medical researchers refined their AI algorithms using a few carefully curated databases, usually anonymized medical information from patients taking part in clinical studies.

However, improving these models further means they need a larger dataset with real-world patient information. Researchers could pool data from several hospitals into one database, but that means asking them to hand over sensitive and highly regulated information. Sending patient information outside a hospital’s firewall is a big risk, so getting permission can be a long and legally complicated process. National privacy laws and the EU’s GDPR law set strict rules on sharing a patient’s personal information.

So instead, medical researchers are sending their AI model to hospitals so it can analyze a dataset while staying within the hospital’s firewall.

Typically, doctors first identify eligible patients for a study, select any clinical data they need for training, confirm its accuracy, and then organize it on a local database. The database is then placed onto a server at the hospital that is linked to the federated learning AI software. Once the software receives instructions from the researchers, it can work its AI magic, training itself with the hospital’s local data to find specific disease trends.

Every so often, this trained model is then sent back to a central server, where it joins models from other hospitals. An aggregation method processes these trained models to update the original model. For example, Google’s popular FedAvg aggregation algorithm takes each element of the trained models’ parameters and creates an average. Each average becomes part of the model update, with their input to the aggregate model weighted proportionally to the size of their training dataset.

In other words, how these models change gets aggregated in the central server to create an updated “consensus model.” This consensus model is then sent back to each hospital’s local database to be trained once again. The cycle continues until researchers judge the final consensus model to be accurate enough. (There’s a review of this process available.)

This keeps both sides happy. For hospitals, it helps preserve privacy since information sent back to the central server is anonymous; personal information never crosses the hospital’s firewall. It also means machine/AI learning can reach its full potential by training on real-world data so researchers get less biased results that are more likely to be sensitive to niche diseases.

Over the past few years, there has been a boom in research using this method. For example, in 2021, Summers and others used federated learning to see whether they could predict diabetes from CT scans of abdomens.

“We found that there were signatures of diabetes on the CT scanner [for] the pancreas that preceded the diagnosis of diabetes by as much as seven years,” said Summers. “That got us very excited that we might be able to help patients that are at risk.”

What do Threads, Mastodon, and hospital records have in common? Read More »

supreme-court-denies-epic-v.-apple-petitions,-opening-up-ios-payment-options

Supreme Court denies Epic v. Apple petitions, opening up iOS payment options

Epic v. Apple —

Most of Epic’s arguments are moot now, but one point will change the App Store.

Fortnite characters looking across the many islands and vast realm of the game.

Enlarge / Artist’s conception of iOS developers after today’s Supreme Court ruling, surveying a new landscape of payment options and subscription signaling.

Epic Games

The Supreme Court declined to hear either of the petitions resulting from the multi-year, multi-court Epic v. Apple antitrust dispute. That leaves most of Epic’s complaints about Apple’s practices unanswered, but the gaming company achieved one victory on pricing notices.

It all started in August 2020, when Epic sought to work around Apple and Google’s app stores and implemented virtual currency purchases directly inside Fortnite. The matter quickly escalated to the courts, with firms like Spotify and Microsoft backing Epic’s claim that Apple’s App Store being the only way to load apps onto an iPhone violated antitrust laws.

The matter reached trial in May 2021. The precise definitions of “games” and “marketplace” were fervently debated. Epic scored a seemingly huge victory in September 2021 when a Northern California judge demanded that Apple allow developers to offer their own payment buttons and communicate with app customers about alternate payment options. An appeals court upheld that Apple’s App Store itself wasn’t a “walled garden” that violated antitrust laws but kept the ruling that Apple had to open up its payments and messaging.

Today’s denial of petitions for certiorari means that Apple has mostly run out of legal options to prevent changes to its App Store policies now that multiple courts have found its “anti-steering” language anticompetitive. Links and messaging from developers should soon be able to send users to alternative payment options for apps rather than forcing them to stay entirely inside Apple’s App Store, resulting in a notable commission for Apple.

Epic’s goals to see Fortnite restored to the App Store or see third-party stores or sideloading on iPhones remain unfulfilled. This is not the case with Epic’s antitrust suit against Google, which in mid-December went strongly in Epic’s favor. With a unanimous jury verdict against Google, a judge this month will determine how to address Google’s violations—potentially including Epic’s request that it and other developers be allowed to issue their own app stores and payment systems on Android devices.

Tim Sweeney, CEO of Epic Games, wrote in a thread on X (formerly Twitter) that the Supreme Court’s denial means the “battle to open iOS to competing stores and payments is lost in the United States” and that it was a “sad outcome for all developers.” Sweeney noted that as of today, developers on Apple’s platforms can “tell US customers about better prices on the web.” And he noted that regulatory and policy actions around the world, including the upcoming EU Digital Markets Act, may have further impact.

Apple has yet to comment on today’s Supreme Court decision.

Supreme Court denies Epic v. Apple petitions, opening up iOS payment options Read More »

with-fewer-pollinators,-plants-are-cutting-back-on-nectar-production

With fewer pollinators, plants are cutting back on nectar production

I can handle this myself —

Fewer pollinators means more self-pollination, less food for bees.

Image of a field of multi-colored flowers.

In a striking experiment, scientists from the French Centre Nationale de la Recherche Scientifique (CNRS) and the University of Montpellier have observed the impact of selective pressure on a flowering plant. By comparing the pansy flower variety of today that grows in the Paris region to those regrown from the seeds of the same variety collected in the 1990s and 2000s, the researchers have observed notable differences.

According to the study’s co-author, Pierre-Oliver Cheptou, the plant’s evolution over this period has resulted in a 25 percent increase in self-pollination (or selfing) in modern two plants. “We also noticed a 10 percent decrease in the flower size and a 20 percent reduction in the nectar production, which suggests the decrease in rewards for pollinators such as bumblebees,” he said.

To confirm this outcome, Cheptou and his colleagues conducted behavioral tests involving bumblebees “which preferred the ancestor plants,” Cheptou said.

He added that the study showed the impact of pollinators’ decline on the reproductive system in these plants.

When mom and dad are the same plant

Elaborating on the experiment techniques, the study’s lead author, Samson Acoca-Pidolle, said the researchers used “resurrection ecology,” which involved using plant seeds from the 1990s and 2000s that were picked from the fields in the Paris region and stored in fridges in two botanical conservatories. “In 2021, we went to the same fields to collect the seeds of the descendants of the same flowering plant,” he said. For the study, all the plants were cultivated in a greenhouse at the same time of year to ensure consistency.

Cheptou said that to determine the selfing rates of the ancestor and descendant varieties, the team used a classical molecular technique that involved measuring the frequency at which individual plants had stretches of chromosomes with identical versions of genes. This happens often in selfing since the maternal and paternal copies of a chromosome come from the same individual.

According to Acoca-Pidolle, the research team was surprised at the rapidity of the plant’s evolution in the natural environment. “It seems that the pollinators’ decline is already strong, and there is already selective pressure on this species. The other significance of the result is that we are currently observing the breakdown in the plant-pollinator interaction for this species,” he added.

Acoca-Pidolle said the study suggests that the decline of pollinators could become self-reinforcing. “If plants produce less nectar, we can predict that pollinators will have less food and this could increase the pollinator decline,” he said.

Everything is a trade-off

This adaptation may not necessarily turn out to be beneficial for the plant. “It depends on the time scale we are considering this adaptation as an answer to the selective pressure. In the long term, we know that selfing species have a higher extinction rate than out-crossing species,” he said.

Although this study was restricted to a single plant species, Cheptou suspects a similar evolutionary adaptation could be taking place in other species, too. “For plants that can practice at least a little selfing, we should expect this result. But this has to be checked by experiments,” he said.

According to Cheptou, future research should investigate if a similar pattern exists in this plant species elsewhere in Europe and see if a similar adaptation has occurred in other species.

“The other interesting aspect would be to see if plants’ future evolution could be reversible, which will again make them more attractive to the pollinators and practice less selfing,” Acoca-Pidolle said.

New Phytologist, 2023. DOI: 10.1111/nph.19422

With fewer pollinators, plants are cutting back on nectar production Read More »

medical-roundup-#1

Medical Roundup #1

Saving up medical and health related stories from several months allowed for much better organizing of them, so I am happy I split these off. I will still post anything more urgent on a faster basis. There’s lots of things here that are fascinating and potentially very important, but I’ve had to prioritize and focus elsewhere, so I hope others pick up various torches.

We have a new malaria vaccine. That’s great. WHO thinks this is not an especially urgent opportunity, or any kind of ‘emergency’ and so wants to wait for months before actually putting shots into arms. So what if we also see reports like ‘cuts infant deaths by 13%’? WHO doing WHO things, WHO Delenda Est and all that. What can we do about this?

Also, EA and everyone else who works in global health needs to do a complete post-mortem of how this was allowed to take so long, and why they couldn’t or didn’t do more to speed things along. There are in particular claims that the 2015-2019 delay was due to lack of funding, despite a malaria vaccine being an Open Phil priority. Saloni Dattani, Rachel Glennerster and Siddhartha Haria write about the long road for Works in Progress. They recommend future use of advance market commitments, which seems like a no brainer first step.

We also have an FDA approved vaccine for chikungunya.

Oh, and also we invented a vaccine for cancer, a huge boost to melanoma treatment.

Katalin Kariko and Drew Weissman win the Nobel Prize for mRNA vaccine technology. Rarely are such decisions this easy. Worth remembering that, in addition to denying me admission despite my status as a legacy, the University of Pennsylvania also refused to allow Kariko a tenure track position, calling her ‘not of faculty quality,’ and laughed at her leaving for BioNTech, especially when they refer to this as ‘Penn’s historic research team.’

Did you also know that Katalin’s advisor threatened to have her deported if she switched labs, and attempted to follow through on that threat?

I also need to note the deep disappointment in Elon Musk, who even a few months ago was continuing to throw shade on the Covid vaccines.

And what do we do more generally about the fact that there are quite a lot of takes that one has reason to be nervous to say out loud, seem likely to be true, and also are endorsed by the majority of the population?

When we discovered all the vaccines. Progress continues. We need to go faster.

Reflections on what happened with medical start-up Alvea. They proved you could move much faster on vaccine development than anyone would admit, but then found that there was insufficient commercial or philanthropic demand for doing so to make it worth everyone’s time, so they wound down. As an individual and as a civilization, you get what you pay for.

Researchers discover what they call an on/off switch for breast cancer. Not clear yet how to use this to help patients.

London hospital uses competent execution on basic 1950s operations management, increases surgical efficiency by a factor of about five. Teams similar to a Formula 1 pit crew cut sterilization times from 40 minutes to 2. One room does anesthesia on the next patient while the other operates on the current one. There seems to be no reason this could not be implemented everywhere, other than lack of will?

Dementia rates down 13% over the past 25 years, for unclear reasons.

Sarah Constantin explores possibilities for cognitive enhancement. We have not yet tried many of the things one would try.

We found a way to suppress specific immune reactions, rather than having to suppress immune reactions in general, opening up the way to potentially fully curing a whole host of autoimmune disorders. Yes, in mice, of course it’s in mice, so don’t get overexcited.

From Sarah Constantin, The Enchippening of Medical Imaging. We are getting increasingly good not only at imaging, but imaging with smaller and more mobile and cheaper devices, opening up lots of new potential applications. An exciting time. As Sarah notes more broadly to open the series, making cheaper and better chips is the core tech behind pretty much everything getting continuously cheaper and better, and you should expect continuously cheaper and better from anything that relies on chips.

She also notes that Ultrasound Neuromodulation is potentially very exciting, especially if it can be put into a wearable. We could gain control over our mental state.

Claim that Viagra was significantly associated with a 69% reduced risk of Alzheimer’s Disease. Nice. There are supposed mechanisms involved and everything, the theory being direct brain health effects and reductions in toxic proteins that cause dementia. As opposed to the obvious interaction that Viagra users have more sex than non-users, which might protect against and definitely indicates against dementia.

Experts are, and I quote, warning us ‘not to get our hopes up yet.’

Amazon is now offering medical services, at very low prices. No insurance accepted.

Emily Porter, M.D.: Amazon is now offering chat medical visits (not even video) with physicians and NPs for $35 cash if you think you have COVID. Or a yeast infection. Or need birth control. How is this even considered healthcare? And why is it less expensive than my copay for my $700/mo BCBS PPO?

I want to jump in and say that I actually believe birth control should be OTC (plenty of my past tweets support that). But asthmatics, thyroid patients, those with high blood pressure, etc that Amazon is treating deserve affordable, accessible in-person care. This is suboptimal.

Armand Domalewski: Being able to chat with a doctor within 15 minutes for $30 is amazing. If you had told me this would be possible ten years ago I would’ve been blown away.

Seems great to me. Yes, if your only optimization target is optimal care and presume that everyone would otherwise get the full product, you will favor vastly more doctor attention, at vastly greater expense. However, if you instead realize that people’s time and money are things that matter to them and to society generally, which also means they will forgo medical consultations and treatments that cost too much of them. And also that we only have so many doctors (thanks AMA!) and thus only so many doctor hours to allocate, so if you waste them where they’re not valuable then someone else misses out, and that we do a lot of that allocation via time rather than price which is even worse. This is all very practical, a lot of people in the spots Amazon is offering a consult would instead have chosen no care at all under our existing system.

Health care would work so much better if we treated it as less sacred and more like Amazon treats its other products.

Economist reports (HT MR) that health insurance providers have a cap on direct profits, so they are buying health providers in order to steer customers to them, then paying those providers arbitrary prices. The incentives were already a nightmare, this makes them that much worse.

An interesting note is that Matthew Yglesias says he thought that this position was the consensus. It is simultaneously the consensus in the sense that people believe it, and also contrarian in the sense that the establishment and public health plan to do it all over again to the maximal extent possible and often act, like they and other cultural would-be authorities do on many things, as if anyone who defies the minority opinion they endorse too loudly is dangerous and terrible.

American Hearth Association releases new clinical tool that removes race as a factor in predicting who will have heart attacks or strokes. They decided that this is not a form of evidence they are willing to use, even though African-Americans suffer more heart attacks and strokes even when you control for everything else we know to measure. Not factoring this in means they will get less care. That doesn’t seem great.

Dylan Matthews makes a convincing case that while deaths of despair and overdose deaths have increased, the bulk of the decline in American life expectancy so far has been due to problems with cardiovascular disease. It is also noted that the decline is focused on the worst-off locations and among high school dropouts, as opposed to being about whether you go to college.

So what matters is whether something in one’s early life is going very wrong. When that happens, we are letting such people down in many ways.

Not that the overdoses don’t matter. We have a rapidly growing, out of control problem with overdose deaths, and it is already having a real impact on life expectancy, and if it continues growing exponentially it will soon be far worse. It is scary as hell.

The right question to ask, as is often the case, is: Is this an ongoing exponential?

It looks exponential. It would be scary anyway since it is already almost 3% of deaths in 2021. What happens if it doubles again in the next decade?

My mind still boggles that asking questions with the intent to learn or prove something requires ‘ethical’ clearance and worries about ‘potential harm’, and people keep endorsing this on reflection, burn it all to the ground.

Keller Scholl: The idea that asking people questions requires approval by an ethics board is a position unique to science/health. A YouTuber can do this and nobody bats an eyelash! But the moment you say you’re trying to do something other than entertain and profit, the “ethics people” arrive.

I want to differentiate them sharply from people who care about ethics, people who do serious ethical reasoning, etc. Primary marker is a bias towards inaction that is stronger when activity is for human advancement. Unlikely to be kidney donors personally.

amolitor.dolt: you kinda want *somethingthough. anyone should check that you’re literally just asking questions and not “while giving them electric shocks” or whatever. scientists get up to some shit if you don’t keep an eye on them.

Keller Scholl: “Asking people questions is fine. If you want to stick needles in them or lock them up, now you need approval from a peer committee with one or two outside voices” is a reasonable standard.

Yes. A simple safe harbor. If all you are doing is talking to people, or ideally also if you are otherwise doing things humans are allowed to do to other humans without any paperwork or checking for ‘informed consent’ then you don’t need any approvals. Even if you have the federal funding. Ask your questions.

A continuous problem is that the world desperately needs more common sense ethics and well-considered ethical considerations, and also that anyone who uses the word ‘ethics’ almost ever has anything to do with either of these things.

United Health pushed employees to follow an algorithm to cut off Medicare patients’ rehab benefits, says StatNews, to the tune of our way or the highway. If you want a ‘human in the loop’ the human needs to be able to determine the outcome of the loop. Here, it seems, they did not.

Yes, a lot of the reason Canadian health care is cheaper is that they sometimes tell you they’re not going to give you the surgery and instead suggest you consider assisted dying instead, whereas in America they will operate on you.

Tyler Cowen makes the case for a big push for hospital pricing transparency. As in, we need to insist on this like we insisted on ending the Vietnam War. The current situation is rather dire, as in things like this:

Recent research shows it is hard to even get a single consistent answer from a single provider. For instance, prices posted online and prices quoted over the telephone do not correlate very closely. For 41% of hospitals, the price difference was 50% or more. Clearly, suppliers aren’t really trying.

There is also a bipartisan health-care price transparency bill that was introduced last summer. President Joe Biden’s administration is proposing additional rule changes to further health care price transparency. Both are positive steps.

If all this sounds like too much government intervention, keep in mind the current non-transparent system is very much the product of ill-conceived government intervention, including regulations, entry barriers and trillions of dollars of public money. Most of those policies are not going away, so addressing these problems is going to involve some positive use of government. At the same time, a broader cultural revolution will be necessary.

Quite right on all counts. Government has decided for various reasons to intervene massively in the health care payments system, which is a central reason we lack price transparency. We need to use government to fix this, even if we do not use the first best solution of ‘get out of the way,’ and the benefits would be massive if we did fix it.

Paper claims working from home has negative mental health effects versus a workplace arrangement, although neither a big effect not anything like not working.

When considering all three dimensions of mental health together, WFH causes a 0.087 standard deviation increase in the overall measure of mental health deterioration compared to WP. Conversely, when compared to the NW option, WFH leads to a 0.174 standard deviation decrease in the overall measure of mental health deterioration.

In the context of a pandemic, working from home was probably relatively worse. My model is that the problem comes from isolation. If work was your only contact with the outside world you needed that. If not, you don’t.

Expiration dates are only, like, suggestions, man.

Kevin Kosar: News you can use: “Ah, but these food-safety regulations keep us safe, you might say. In almost all cases, there is no regulation and the dates do nothing to keep us safe.”

Scott Lincicome: An excellent @JoshZumbrun dive [in WSJ] into what I’ve been preaching for years now: so-called “expiration” dates are costly scam.

It took me blindly eating 5-month old yogurt live on camera (and lots of yelling) to do it, but I think I can finally now say it: I won.

The expiration dates are mandated only for infant formula. That does not mean they are useless, not net useful, or not protective of your health. Expiration dates are highly useful as they mark the relative freshness and remaining time of your items, and they provide reasonable approximations on how long various items can remain edible. Does that make them reliable markers of either spoilage or safety? No. It is a problem when sticklers treat them as gospel, again in either or both directions. I’m still glad they are there.

Scott Alexander notes that fully abolishing the FDA would require additional adjustments in the system. How would we deal with liability? What if doctors are stupid or fooled by advertising? How would prescriptions work or not work? How would insurance work? He comes down suggesting the FDA have a safety-only pathway for making drugs allowed, and legalization of artificial supplements.

That would be a reasonable practical compromise, but I think you can go a lot further. All these questions have reasonable answers. Prescriptions can continue where a sufficiently high bar is met, likely with a broader range of who can prescribe (e.g. a pharmacist should be fine for many but not all of them, so you don’t need an extra visit.) The other stuff will sort itself out the way it does everywhere else. Inspection agencies, for example, will rise up that do a better job for less money. Probably we do keep an FDA-like agency around for safety certifications due to liability concerns. To the extent other things wouldn’t fix themselves, it would mostly reveal rather than create those additional problems.

Again, I’d be happy to take Scott’s or another similar compromise. I still want to recognize it is far from first best.

The alternative is not abolishing the FDA and having stories like this?

David Neary: A friend in Spain was feeling unwell and took a covid test. The good news is it’s not covid. The bad news it is the flu. The astonishing news is Spanish covid tests are dual-Covid/flu tests and why in the hell are these not available everywhere?!

Aaron: haha people might want to send home kids with the flu? lol fuck those people, right?

Medic Kim: Why don’t we have at-home antigen tests? Because the FDA panels are composed of these people:

A 2016 FDA advisory_panel, meanwhile, was split on whether the benefits of over-the-counter influenza tests outweighed the risks. Meeting transcripts show that as experts debated whether at-home tests would actually be effective at keeping people at home if they knew they or their children had the flu, one panelist joked that daycare centers might make the decision for parents if over-the- counter tests were available.

“The woman is going to want to go to work, and she wants to drop her kids off at daycare,” the panelist said. “The daycare, when they sign their contract, [could say] ‘If your kid has symptoms, we’re going to test him,” and send the child home if they tested positive.

The room laughed at the idea.

Chair: Looks like they were concerned abt the public’s inability to correctly assimilate false positive / false negative rates, resulting in harmful overconfidence in kit results.

So, yeah. I’ll take my chances with abolition.

Also, the FDA continues to move forward to regulate lab tests. As Alex Tabarrok says, it is vital that we do not let them, although by the time you read this it will be too late for public comment.

Also, why don’t your cold medicines work? Oh right.

John Arnold: Americans have been wasting billions a year on cold medicines like Sudafed & Benadryl with the active ingredient phenylephrine, despite conclusive evidence they don’t work. But a report published yesterday may finally lead to the removal of these drugs from pharmacy shelves.

FDA approval for these medicines was grandfathered without any clinical trial because the active ingredient was shown to be safe and to work if given intravenously. But, since approval, there have been 4 trials of oral form and all have shown no benefit vs placebo.

It’s a great example of the waste in the healthcare system that leads to high costs/poor outcomes. A vote next week will be a big test whether the FDA follows the science or caves to industry pressure.

The FDA has been monitoring these drugs since 2007 and finally ordered a formal review. From the report, posted yesterday: “We have now come to the initial conclusion that orally administered phenylephrine is not effective as a nasal decongestant.

The reviewers note the harms of continued sales:

– Unnecessary patient & total healthcare costs

– Delay in care

– Potential allergic reactions

– Overdosing given no response to recommended dosage

– Risk of use by children

– Missed opportunity for more effective treatment.

An advisory committee will vote next week whether to recommend removal of the drug from OTC use. If successful, it would go to the full FDA. Patients depend on the FDA to conduct rigorous analysis as to the efficacy of drugs. Let’s hope they correct this mistake.

Baron St. Rev Dr. von Rev: Reminder that fedgov allowed drug makers to substitute phenylephrine (which is useless) for pseudoephedrine in order to hamstring public opposition to their crackdown on the latter. It wasn’t a mistake, it was a con-job.

Will they finally fix it? I am not optimistic. They did vote 16-0 that there is no evidence that phenylephrine does not work.

If the system were otherwise sane, I would have zero problem with people selling a medicine that does not work. People could make their own choices. Alas, given the say the rest of the system works, permission, like retweets, here is an endorsement, and results in this preventing other actually effective treatment.

As Nate Silver reminds us, the Covid vaccine was the one thing that we know worked to prevent Covid deaths. Red states had 35% higher death rates than blue states once the vaccine was available, but had similar death rates before that despite less stringent countermeasures, so the effectiveness of all other measures remains unclear.

Former NIH director Francis Collins says the quiet parts out loud (1: 18 video, worth watching) regarding Covid policy and the public health mindset. They don’t think about the impact on the lives of ordinary people. They don’t do trade-offs or think about cost-benefit. They care only about lives saved, to which they attach infinite value.

I thank him for the clarity. Let this be common knowledge. Then let us never again entrust any future public health decisions to anyone with this ‘public health mindset.’

Instead, public health carries on as if they were right all along, even calling for us to mask up again every so often, and we sometimes see cases such as this one: San Diego State University to require Covid boosters in order to attend. Our colleges never learn, yet we expect them to teach us. What will we do about it?

Some good news on Covid is new claims that vaccination before first infection greatly.

Another good news note that hasn’t been noticed enough:

Steve Sailer: Here’s one observation about the contentious history of the pandemic I’ve never seen anywhere: Hospital managers turned out to be better at juggling their resources to keep their facilities from being overwhelmed than anybody had expected them to be.

This was the dog that did not bark. By all accounts, hospitals should have been far more overwhelmed, in ways that caused a lot more degradations in care and many excess deaths. Indeed, health care workers were constantly reporting hellish conditions, being put under unbearable pressures. Yet in the end, at least after the very early days, the center almost entirely held. We never properly thanked or honored those who pulled this off, in any form. Nor have we updated our future anticipations.

House passes ban on toddler mask mandates without a vote after opposition fails to provide any evidence whatsoever that masking toddlers is helpful. Took long enough. Turns out people say things are evidence-based without, ya know, evidence.

Several Republican Congressmen including Rubio told Biden on December 1 to ban travel from China to prevent mystery illness spread. And of course the person posting this was claiming there is no difference between this and lockdowns and this makes Republicans hypocrites. It doesn’t. It does make them wrong, in the sense that such a rule would have accomplished nothing even if the mystery illness had mattered – it is difficult imagine the world where such a ban stops the spread that would have otherwise happened. Luckily, we didn’t ban travel and everything is fine.

Nate Silver continues to be loud about the ‘Proximal Origins’ paper, the damage it and related efforts to convince us we could assume natural origins of Covid have done to trust in science, and in particular the lack of willingness to admit and call out what happened. He links to this post about it. Things do not look better over time:

Paul Thacker (from a larger thread): @USRightToKnow released documents showing virologists & Wuhan researchers attempted to mislead on a DARPA grant–they hid that they would do some dangerous virus research in Wuhan. Right where the pandemic started.

Nate Silver: This is quite bad. A group of virologists wanted to do gain-of-function research on COVID viruses in Wuhan in ways that closely matched the SARS-CoV-2 virus that’s killed 8+ million, but tried to hide the Wuhan linkages and got a lot of help in doing so from science journalists.

Idk COVID killed 8m people officially and tens of millions unofficially (based on excess deaths) and also profoundly disrupted nearly everyone’s well-being for 6-18 months, seems like a pretty important one compared to all the dumb shit people usually argue about.

The responses attempting to defend natural origin are all essentially ad hominem attacks at this point. The wrong person is advocating, why are you amplifying this bad person and bad theory, you do not know what you are talking about. Never arguments about the facts.

Here is a thread summarizing many pieces of evidence in favor of a lab leak.

If you want to engage with the debate, well, good news, it seems there is an 18 hour recorded debate, a third of which is published, six figures at stake on the outcome and a prediction market on the outcome.

Daniel Filan: One thing I’d like to emphasize: I think this is the best debate I have seen in my life. Object level informative, and worth wondering how to emulate. I genuinely wish political debates had this format.

I still am not about to watch hours of that.

The prior should not be low:

William Eden: The prior on lab leaks happening IS NOT LOW. It does NOT require extraordinary evidence for a lab leak being a source of an outbreak. This is always a reasonable hypothesis and *must be investigated*

Ian Birrell: New study reports 309 lab acquired infections and 16 pathogen lab escapes between 2000 and 2021

If we have almost one confirmed lab leak per year, and given the other circumstances, it would almost be surprising if Covid-19 wasn’t a lab leak.

Was Covid a lab leak? We don’t know. At this point it seems more likely than not.

That statement should drive huge changes in policy. A lot of people should be rethinking quite a lot of things. That is true even if (as I expect) we never know the answer for sure. This is very similar to the question of existential risk from AI. Any reasonable person, given the evidence, should say the lab leak has substantial probability, as does natural origin. Once you think the number is substantial, it does not much matter if your probability of the lab leak is 30%, 50%, 70% or 90%. They should drive most of the same changes in policy, and the same reflections. They won’t.

Imagine how we and you would have reacted if we had known, back in February 2020, that this virus had escaped from a lab. Then ask which parts of that reaction you would endorse on reflection, and which you do would not. Then act accordingly.

The good news is that it likely has succeeded in at least cancelling Deep VZN.

Jonatan Pallesen: The lab leak discourse has probably already succeeded in cancelling Deep VZN. An absurdly dangerous project where they would go and seek out the viruses most able to cause pandemics in humans. This alone makes it a debate that has achieved more than most others.

You think this is the worst that can happen? Well, remember that time Australian researchers were actively trying to create a ‘contraceptive mouse virus’ for pest control, which is totally not how any science fiction dystopia stories start, and they instead accidentally created a modified mousepox virus with 100% mortality? Check the linked thread out, because it keeps… getting… worse.

House unanimously votes to defund gain-of-function experiments with potential pandemic pathogens. I would prefer a ban, but unanimous support for at least not paying for it is a great start. Why am I worried this will still not get implemented?

Reducing third world lead poisoning continues to be a plausible high-value cause area.

Nathan Young: For a lack of, lets say, $1bn, half the children in poor countries have lead poisoning.

Jesse Copelyn in The Guardian: An estimated $350m in targeted aid from 2024 to 2030 would be enough to dramatically reduce lead exposure in lower-income countries, provided there is enough engagement from political leaders, according to the CGD. Funding requirements include donations for lead-testing equipment, support with advocacy and awareness campaigns, and technical assistance with drafting and enforcing regulations.

Statements like Nathan’s require caution and careful calibration. I very much doubt a billion dollars would put a stop to all the lead poisoning. How much would it reduce such lead poisoning for how many children, with how much impact? I have no idea. I find it likely that $1 billion well-spent on this would be a good use of funds. I also can think of ways one could plausibly spend that money badly, and it ends up wasted or even making things worse.

Seriously, let’s buy out the patent rights and offer these drugs for free to anyone who wants them, what are we waiting for. New EA cause area.

Belarusian comedian hits it big with comedy routine (YouTube, 1: 04: 00) in which he complains he will die of old age and calls upon everyone to focus on maybe stopping this from happening.

Robert Wiblin: Paying people in exchange for their blood is very bad — but saying misleading things so they’ll give you their blood for free is very good.

The expected QALYs from you donating blood is more like 0.01 rather than the 200 which they’re suggesting. Still a good thing to do but you can’t save 3 lives in an hour.

Excellent, I don’t remember seeing a good estimate before, 0.01 seems highly sane. So that’s about three days of life. A very good thing to do, definitely donate blood. Very, very different from three lives in an hour, not even the most outlandish EA earning-to-give and cost-per-life-saved statistics claim anything close to that.

Rob Bensinger: Seems like one of the more important facts about our civilization — we live in the world where paying people is seen as taking advantage of them, while lying to people is seen as normal and OK. (In a surprisingly large number of cases.)

I think a lot of what’s going on is that “was money exchanged?” is a relatively discrete and legible question, whereas “was a falsehood stated?” is often a lot fuzzier, depending on how vague language is interpreted, and on where you draw various lines.

An eight year old watching a webcam feed can tell with confidence whether money was exchanged, typically.

Whereas the entire Earth’s resources, science, and technology can’t necessarily reach a confident verdict about whether Alice’s “I’m fine” statement is strictly true. (Even Alice may not be confident!)

So bureaucracies have a much easier type setting actionable policies about money than about truthfulness. And individual humans have a far easier time rationalizing their preferred conclusion about “was X true?” than about “was Y paid?”.

The end result being that bureaucracies end up with all sorts of wacky rules about money, because humans have emotional hang-ups about Everything and money is an easy thing to regulate.

Whereas even the most scrupulous bureaucracy will tend to lie a lot, because this is harder to regulate and incentive gradients toward lying abound: you fudge the truth a tiny bit and it helps, then you fudge it slightly more…

I doubt anyone in the bureaucracy ever had the conscious thought “it’s OK to fudge the truth and deceive people, but not OK to pay them”. Lying and paying people are just very standard human behaviors, and of those “paying people” is a lot easier to regulate.

Want to get more people to donate? Yes, you could and should pay them. There is some price at which you’ll get plenty of donations, it will be cheap versus health gains, and those that get the money will be better off.

But also I once again iterate to those in charge of blood donations: By requiring appointments, you are greatly raising the effective cost of donations. If you could take walk-ins, even confirmed right beforehand on the web, I would happy do this much more often. If I have to block out an appointment time days in advance, that’s so much harder.

That change fits well within the ‘ethics’ requirements. All you have to do is provide a place I can walk in on a whim and donate, or go when there is urgent need. I’ll do it.

You know who else you should pay? The head of UK pandemic preparedness.

Alex Tabarrok: What’s the chance it could happen twice? ¯_(ツ)_/¯

Wegovy (a GLP-1 antagonist) cut the rate of major heart problems in a 17k patient trial – heart attack, stroke, or cardiovascular-related death by 20%. It also cut all-cause mortality by 19%, which I would have led with, with no major side effect issues. Wow.

Market Monetarist thinks GLP-1s are a huge economic deal.

Obesity, particularly severe obesity, involves enormous healthcare costs. In the United States, the rate of obesity has increased markedly since the 1980s. Now, approximately 40% of the population is obese, leading to stagnation in average life expectancy and making obesity-related diseases like diabetes and heart disease among the leading causes of death.

A Danish study from 2021 showed that healthcare costs for obese individuals are double those for individuals of normal weight, significantly contributing to the national healthcare burden in Denmark. The reduction of severe obesity through medications like Ozempic and Wegovy could provide a substantial economic boost.

America spends more than 17% of GDP on health care. If GLP-1s reliably cure obesity, and obesity doubles health care costs, and 42% of Americans are obese, the math says that you could in theory reduce health care costs by almost 30%, saving almost 6% of GDP.

That is a huge game, if and only if that spending does not then get reallocated to providing more care to others. If our health spending is determined more by wealth than medical need, as it seems largely to be, most of that would be wasted on additional marginal care of little value.

The actual health benefits, of course, would be very real, including productivity.

Obese individuals are also less productive, more likely to be unemployed, and earn lower wages. This translates into substantial economic impacts, such as higher rates of work absenteeism among severely obese workers compared to their normal-weight counterparts.

A reduction in obesity in the U.S. could lead to an improvement in the economy. Halving the number of obese individuals could result in a 2% increase in overall wages and a significant rise in GDP if we assume as numerous studies shows that obese women have salaries 10% lower than normal weight women (corrected to age, education and experience).

I would be cautious attributing too much of the earnings differential to productivity. The beauty premium is real, discrimination against ugly or fat people is rampant, and these are likely to largely be positional effects.

Still, there are obviously large real productivity gains to better health.

There are also big productivity gains to general impulse control. GLP-1 inhibitors help with a wide variety of addictive and unproductive behaviors. My presumption is you would see substantial productivity gains.

How best to think about what Ozempic (another GLP-1 antagonist) does?

Cate Hall: Ozempic doesn’t provide willpower; it eliminates the need for it. These might sound like similar things but the internal experience is wildly different, as any addict can tell you.

Andy Jung: Translation: it doesn’t give you the willpower to overcome unhealthy urges. It eliminates the urges. Really interesting…powerful, but ultimately a shortcut.

Cate Hall: Hell yeah, we love shortcuts!

Emmett Shear: Will power basically doesn’t exist as far as I can tell?

Cate Hall: I think that’s a defensible position. It’s certainly at least a confused concept. I would probably say willpower in the sense of gritty determination exists, but in application doesn’t look anything like what “alcoholism is just poor willpower” folks think.

I think this is one of those places where willpower is a confused concept when you look at it too carefully, but acting like it does not exist or is not important will only leave you far more confused. I find it wise to treat willpower as if it is real.

How much adaptation will we see? It is easy to do the math on every obese person taking Ozempic. It is a lot harder to get that to happen, or anything approaching that.

Ozempic might be driving a selloff in candy and beer stocks, with the caveat that of course one must never reason from a price change.

Genevieve Roch-Decter: Weight loss drug Ozempic causing selloff in candy and beer stocks, per Bloomberg. Walmart said it’s already seeing an impact on shopping demand from people taking Ozempic. That sent shares of food and beverage companies sliding, some to multiyear lows. Crazy.

This is super exciting. As with AI, this part of the future remains highly unevenly distributed, and is orders of magnitude more expensive than it will be soon.

Tenobrus: it turns out ozempic is also the cure for doomscrolling and tiktok

Ava: something amazing about the fact that we invented things we’re incapable of consuming in moderation and then invented something that removes our ability to enjoy them.

It looks like GLP-1s reduce alcoholism, which on its own is a huge freaking deal.

Does… this… work? Issue hasn’t come up for me in a while:

Iva Dixit: Constantly stupefied at how if I google a medication name with the word “coupon” and show the pharmacist the first result from a shady looking spammy site — 90% of the time it works and the medicine’s price goes from $283 to $31.

I have just been told that if I get this medicine delivered via their home delivery program it’s $60 and if I want to come pick it up myself then it’s $142 ………………. big pharma are you guys ok.

I mean, I googled ‘Ozempic coupon’ as a test – note that these are very much the opposite of verified – Henry Meds claims to be selling a GLP-1 antagonist at $300/month, Calibrate claims even less, GoodRx has modest (~10%) discounts off the bat.

Also does this work? A public service announcement blast from the past.

Karandeep Singh: The more friction that exists in US healthcare, the more that innovation ends up looking like this 👇

Matt Yglesias shares his experience losing weight via bariatric surgery. He found it easy to lose weight up to a point, but that past that point he continued to struggle with the same urges to eat more and eat unhealthy and not be active. He’s excited for the GLP-1 inhibitors. One worthy note he makes is that if you have an unhealthy relationship to food, fixing it is (usually, for most people, myself included) not a matter of ‘eat like a healthy person,’ the same way an alcoholic can’t drink like a normal person. You have to do something far more intentional and deliberate, more absolute, more costly, and do it constantly forever. The other is that he sees anticipation that doctors will lecture fat people that they should lose weight as a big barrier to them effectively getting any other treatment for problems their weight makes worse – not only don’t they want to hear it, the doctors often refuse to offer alternative help. Which is terrible, and doctors should of course stop it, especially the not helping with alternatives. Yet we also would be wise to find ways not to generally fool ourselves into thinking that unhealthy weights are healthy.

An epic and righteous rant about how much people obsess over vegetables and what is rightfully called morality-based dietary planning. Eigenrobot’s 100-year-old grandfather is literally starving to death because his grandmother keeps insisting on these elaborate ‘healthy’ meal plans that took him hours to consume, when instead it turns out you can just feed the guy stuff like ice cream and he can get it down fine, and obviously that is what any sane person would do in this spot.

My model is that we know four things about nutrition with any certainty:

  1. Different people work very, very differently here.

  2. There are things you need, often but not always your body lets you know.

  3. Vegetables good.

  4. Sugar bad.

How important are rules two and three? Great question. We don’t know that.

I’ve been unable to eat fruits or vegetables in most forms for my whole life, unless they are very tiny or heavily processed. My body does not believe they are food and I will literally gag and choke on them. The few ways I can sometimes eat one almost never bring me any joy, only melancholy and sorrow. People constantly worried about this for a long time, and I haven’t been able to fix it. I don’t worry much about this anymore, and you know what? It’s fine.

On rule three, my revealed preference is ‘enough to eat less sugar than I otherwise would, not enough to not eat a lot of sugar anyway.’ I endorse this on reflection.

What are the returns to exercise? Roger Silk does some math, attempting to think like an economist.

His basic model is to assume that we value 16 waking hours per day only, exercise costs time now, and it pays off with additional time in the future. He then asks, if a program of 9 hours gives a 50-year-old the chance to live to 88 instead of 80, what is the rate of return? He finds 5.8%, with returns up to 6.5% for smaller investments, so the marginal return on the final hours is likely more like 4%.

Is that a good investment? As Roger points out, there is no inflation in years. If all things were fully equal, and all that mattered was my personal time discounting, and I thought I ‘lived in normal times’ so to speak so postponing my actions didn’t impact the world nor would the world much change, I would take essentially any positive return.

What key considerations are being ignored in the calculation here?

  1. Correlation is not causation. Exercise is claimed to be ‘associated’ with 8 extra years of life. But it is trivial to see why this is almost certainly an overstatement of the causal effect of choosing more exercise. Choosing to do more and better exercise is associated with good health through direct causation, and also associated with most other good habits and attributes. A brief look at the study indicates no effort to account to properly control for these problems.

  2. Exercise has major positive impacts other than lifespan. This is the reason why I am able to motivate myself to exercise. If it was purely lifespan, I would not trust that the rate of return was positive. But when I exercise, I have more energy, I feel better, I look better, I can eat more, life is good. That is a huge deal.

  3. Exercise can be good or bad in many other ways. Are you using up willpower or generating more? Learning to form good habits, or using up your habit budget? Does this make you more interesting and confident, or less interesting and overconfident? Do you start loving life, or start hating life? Different people get different results, on top of the considerations I mentioned earlier.

  4. As is noted, what kind of years are you getting? Are you getting extra healthy years, extra aged years on the end, or a slowing of the aging process? How exactly does this all supposedly work? You are investing your best remaining years now (at least if we are assuming you are at least 25 now), in terms of health, to get years later. If the average future year quality doesn’t change, you are downgrading quite a bit on health. You could make some of it up with wisdom and wealth.

  5. You could also make up for it via future technology. If you expect technology to extend our lifespans over time, then buying time becomes more valuable. If you expect escape velocity, expected returns could suddenly look very, very good. Same if you think that new tech will make life a lot better in at least some worlds. If I am alive in 2054, then chances are some really awesome tech is available.

  6. The time you spend exercising is not worth zero. If you hate it, it could be strongly negative. If you find something you like, or a way to like it, it can be substantially positive. I have yet to find exercise I actively enjoy that I can sustain (I started to like running then my knees gave out), but I have at times found exercise where the net experience is positive due to ability to watch television or listen to podcasts while doing it, or to chat with my trainer.

  7. We do not have 16 flexible, valuable hours to spend each day. There are a lot of fixed costs beyond sleeping that eat into our time. Where is your exercise time going to come from? The more your joy is contained in your copious free time, and the more of that this would eat, the higher the effective price. When I was working at Jane Street, it was a relatively high effective cost in time to work out, whereas now as a writer it is relatively less.

  8. Risk of injury is a real thing, with exercise both causing it directly and preventing it indirectly. I recently took out my back for a few weeks while doing squats in the wrong way, that is important lost time.

Also, the real story of people not exercising is pretty damn simple. Mostly true story.

Afro—Arakkii Leo Says Resist: most people don’t exercise because it’s fucking boring dude. That’s it. It’s literally boring as hell. Especially things like weightlifting, which is 9/10 times just grinding for vanity reasons. And people are always going to be iffy about it until we normalize play as exercise.

Most people don’t want to just go to some sweaty building and hate their bodies into something society deems acceptable like you know what would be great for heart health? Tag. We should all go to the park and play tag.

But i’m so sick of gym bros shitting on people for not wanting to exercise like bro….this shit isn’t natural. Picking heavy things up over and over again to look bigger is something we just made up! And it’s not even fun!

I would take the under on 90% vanity. A lot of working out is for the right reasons. But yes, working out is mostly unpleasant and boring as hell as we conceive of it and we need to stop pretending otherwise. Once we agree that most exercise mostly bores most people who try it out of their minds, we can work on not doing that.

Well, maybe. From a certain point of view.

Matthew Yglesias takes a stand against dentistry. Well, maybe not quite against dentistry writ large, but against the current regime of dentists being a cartel taking a large cut of every cleaning, not letting others diagnose conditions, and the only insurance available being a product that does not insure one against large dental bills, while not providing evidence for its interventions working.

Studies show, he says, that letting dental hygienists work on their own improves dental health, in addition to improving equality and lowering costs. The mechanism is that if routine dental services cost more, you will consume less of them.

The insurance thing is its own complaint and also pretty weird every time I think about it. In medicine you want to buy medical catastrophic insurance and are forced to also buy coverage on pain of them charging you artificially high prices to punish you. In dentistry, you cannot buy the insurance at all even together with the coverage, only partial coverage of routine costs.

Most interesting is the claim that dentistry is not evidence based.

Matthew Yglesias: Dental medicine is practiced with almost no scientific evidence, making it a huge field of opportunity for grifts and scams.

The Matthew Principle (no relation I think): I’ve had similar experiences: went to a dentist once and was told I had seven (!) cavities. Went to another and was told there were just two.

Adrienne: This happened to my mom. Went to a new dentist and was told she needed about $7,000 of work. Got a second opinion, and nothing was wrong.

Alicia Smith: Friend of mine went to the dentists and was told she had 3 cavities since her last visit a year ago. She went and got a 2nd opinion before getting these cavities filled, and was told she has no cavities at all.

[comments full of people who don’t trust dentists not to defraud them.]

Matt Yglesias (in his post): Some people, of course, are not that ethical. And even those who are ethical are naturally going to find themselves inclined in the direction of self-interest when dealing with an evidentiary void. William Ecenbarger did a great investigative report for Readers’ Digest years ago where he visited dentists in different cities and asked for their recommendations and got prescribed courses of treatment ranging from $500 to $25,000. One outfit in Philadelphia diagnosed him this way: “Tell me what your insurance limits are, and we’ll proceed from there.”

Back at Vox, I used to work with Joey Stromberg (whose dad is a dentist), who wrote a piece about how “while seeing other dentists, my brother has been told he needed six fillings that turned out to be totally unnecessary (based on my dad’s look at his X-rays) and I’ve been pressured to buy prescription toothpaste and other products I didn’t need.” Aspen Dental appears to have built a whole corporate dental chain around the observation that you can attract patients with low prices and then make it up in volume by prescribing unnecessary treatments.

Yglesias also quotes Ferris Jabr in the Atlantic here:

The Cochrane organization, a highly respected arbiter of evidence-based medicine, has conducted systematic reviews of oral-health studies since 1999. In these reviews, researchers analyze the scientific literature on a particular dental intervention, focusing on the most rigorous and well-designed studies. In some cases, the findings clearly justify a given procedure. For example, dental sealants—liquid plastics painted onto the pits and grooves of teeth like nail polish—reduce tooth decay in children and have no known risks. (Despite this, they are not widely used, possibly because they are too simple and inexpensive to earn dentists much money.) But most of the Cochrane reviews reach one of two disheartening conclusions: Either the available evidence fails to confirm the purported benefits of a given dental intervention, or there is simply not enough research to say anything substantive one way or another.

And perhaps it gets worse? Here’s MF Bloom quoting the AP saying there is no evidence that flossing works. The government seems to have agreed that no one has ever properly researched the question. The AP looked and its findings where that the evidence is “weak, very unreliable” and of “very low” quality. Ouch.

Does flossing do something? It is a physical action, so we can tell that it does literally do something. But does that something translate into better dental health? We do not know. It would be unsurprising to me either way. I can also see why there could be no one party with the incentive to study this properly and find out.

Medical Roundup #1 Read More »

the-5-most-interesting-pc-monitors-from-ces-2024

The 5 most interesting PC monitors from CES 2024

Dell UltraSharp 40 Curved Thunderbolt Hub Monitor (U4025QW)

Enlarge / Dell’s upcoming UltraSharp U4025QW.

Scharon Harding

Each year, the Consumer Electronics show brings a ton of new computer monitor announcements, and it’s often difficult to figure out what’s worth paying attention to. When it comes to the most interesting models this year, there were two noteworthy themes.

First of all, my complaint in 2022 about there not being enough OLED monitors was largely addressed this year. CES revealed many plans for OLED monitors in 2024, with a good number of those screens set to be appropriately sized for desktops. That includes the introduction of 32-inch, non-curved QD-OLED options and other smaller screens for people who have been waiting for OLED monitors in more varied form factors.

Secondly, with more people blending their work and home lives these days, CES brought hints that the line between gaming monitors and premium monitors used for general or even professional purposes will be blurring more in the future. We’re not at the point where the best productivity monitor and ideal gaming monitor perfectly align in a single product. But this week’s announcements have me imagining ways that future monitors could better serve users with serious work and play interests.

For now, here are the most intriguing monitors from CES 2024.

Dell UltraSharps hit 120 Hz

  • Dell started adding 120 Hz models to its UltraSharp series.

    Scharon Harding

  • This monitor is VESA DisplayHDR 600-certified.

    Dell

  • Ports include Thunderbolt 4 with 140 W power delivery. There’s also a pop-out box of ports by the monitor’s chin.

    Dell

Dell UltraSharp monitors have long attracted workers and creatives and, with their USB-C connectivity, even Mac users. The last few CES shows have shown Dell attempting to improve its lineup, with the most landmark innovation being the introduction of IPS Black. With CES 2024, though, Dell focused on improved video resolution.

Dell’s UltraSharp 40 Curved Thunderbolt Hub Monitor (U4025QW), pictured above, is a 39.7-inch ultrawide with a 5120×2160 resolution and a 120 Hz refresh rate. As most monitors are aimed at workers still using 60 Hz, this is a big step up for people with systems capable of supporting 11,059,200 pixels at 120 frames per second. Such speeds have been relegated to gaming monitors for a while, but with TVs moving to higher refresh rates (with encouragement from gaming consoles), more people are becoming accustomed to faster screens. And with other attributes, like a 2500R curve, we wouldn’t blame workers for doing some light gaming on the U4025QW, too.

But Dell says the refresh rate boost is about increasing eye comfort. The UltraSharp U4025QW is one of two monitors with 5-star certification from TÜV Rheinland’s new Eye Comfort program, which Dell helped create, a Dell spokesperson told me last month at a press event.

According to TÜV, the certification program “is no longer limited to the old low-blue-light or flicker-free labels” and now “covers a broader range of safety indicators, such as ambient brightness, color temperature adjustment and regulation, and brightness.” New requirements include brightness and color temperature control for different ambient lighting. Dell’s ultrawide covers this with an integrated ambient light sensor.

The certification also requires a minimum 120 Hz refresh rate, which is probably where Dell got the number from. A Dell spokesperson confirmed to Ars that the use of IPS Black didn’t impact the monitor’s ability to get TÜV certifications and that it could have theoretically earned five stars with another panel type, like VA.

Dell announced bringing 120 Hz to the UltraSharp lineup in November when it debuted two 24-inch and two 27-inch UltraSharp monitors with 120 Hz refresh rates. At CES, Dell proved this upgrade wasn’t a fluke relegated to its smaller UltraSharps and went all in, bringing the refresh rate to a top-line ultrawide 5K Thunderbolt 4 monitor.

The U4025QW has an updated version of ComfortView Plus, which uses hardware to lower blue light levels. I’ve seen it function without making colors turn yellowish, as some other blue-light-fighting techniques do. After not significantly updating ComfortView Plus since its 2020 release, Dell now says it’s using a “more advanced LED backlight” to reduce blue light exposure from 50 percent to under 35 percent.

The effects are minimal, though. Dell-provided numbers claim the reduced blue light exposure could reduce eye fatigue by 8 percent after 50 minutes, but we should take that with a grain of salt. It’s nearly impossible to quantify how well blue light reduction techniques work from person to person.

The UltraSharp U4025QW releases on February 27, starting at $2,400.

The 5 most interesting PC monitors from CES 2024 Read More »

spacex-sues-us-labor-board,-claims-agency-structure-is-unconstitutional

SpaceX sues US labor board, claims agency structure is unconstitutional

Elon Musk on stage at an event, resting his chin on his hand

Enlarge / Elon Musk at an AI event with Britain Prime Minister Rishi Sunak in London on Thursday, Nov. 2, 2023.

Getty Images | WPA Pool

After being charged with illegally firing workers who criticized Elon Musk, SpaceX yesterday sued the National Labor Relations Board (NLRB) in a lawsuit that claims the US labor agency’s structure is unconstitutional.

On Wednesday, an NLRB regional director filed a complaint against SpaceX alleging that it illegally fired eight employees who drafted and distributed an open letter about Musk in 2022. If SpaceX doesn’t settle the charges, the company is scheduled to face a hearing with an NLRB administrative law judge (ALJ) starting on March 5.

SpaceX filed its lawsuit against the NLRB in US District Court for the Southern District of Texas, claiming that the NLRB structure violates US law because the administrative law judge cannot be removed by the president of the United States. SpaceX made a virtually identically argument recently when it sued the US attorney general and two other Department of Justice officials in an attempt to stop a separate hiring-discrimination case.

“NLRB ALJs are ‘Officers of the United States’ under the Constitution’s Appointments Clause—not mere employees—because among other things, they hold continuing offices through which they preside over adversarial hearings, receive testimony, shape the administrative record, and prepare proposed findings and opinions,” SpaceX argued.

SpaceX: “The very definition of tyranny”

The NLRB administrative law judges have “at least two layers of removal protection,” which “prevents that exercise of presidential authority and thus violates Article II of the Constitution,” SpaceX told the court. “But for these unlawful removal restrictions, either the ALJ assigned to SpaceX’s administrative case or the NLRB Members who bear responsibility to supervise and exercise control over the ALJ would face the prospect of removal by the President based on their conduct during the proceedings.”

Musk’s company asked for a preliminary injunction that would stop the proceeding, saying that “without interim injunctive relief from this Court, SpaceX will be required to undergo an unconstitutional proceeding before an insufficiently accountable agency official.”

The NLRB declined to comment today on SpaceX’s lawsuit. The NLRB complaint and notice of hearing to SpaceX said that during the scheduled administrative hearing, the company has “the right to call, examine, and cross-examine witnesses and to introduce into the record documents and other evidence.”

SpaceX’s lawsuit argues that NLRB members act as both prosecutor and judge. Quoting The Federalist No. 47 by James Madison, SpaceX wrote that the “NLRB’s current way of functioning is miles away from the traditional understanding of the separation of powers, which views ‘[t]he accumulation of all powers legislative, executive and judiciary in the same hands’ as ‘the very definition of tyranny.'”

SpaceX is banking in part on an April 2023 Supreme Court ruling in a case involving the Federal Trade Commission and Securities and Exchange Commission. That ruling didn’t resolve challenges to the agencies’ use of administrative law judges, but found that federal district courts have jurisdiction to hear lawsuits over whether the agency structure is unconstitutional.

SpaceX sues US labor board, claims agency structure is unconstitutional Read More »

as-vulcan-nears-debut,-it’s-not-clear-whether-ula-will-live-long-and-prosper

As Vulcan nears debut, it’s not clear whether ULA will live long and prosper

ULA LLAP —

This marks an absolutely pivotal moment for the 20-year-old launch company.

United Launch Alliance hoists the Certification-1 payloads atop the Vulcan rocket in the Vertical Integration Facility adjacent to Space Launch Complex-41 at Cape Canaveral Space Force Station.

Enlarge / United Launch Alliance hoists the Certification-1 payloads atop the Vulcan rocket in the Vertical Integration Facility adjacent to Space Launch Complex-41 at Cape Canaveral Space Force Station.

United Launch Alliance

It’s nearly time. After years of delays, billions of dollars in federal funding, and a spectacular second-stage explosion, the large and impressive Vulcan rocket is finally ready to take flight.

United Launch Alliance’s heavy lift vehicle underwent its final review on Thursday, and the company cleared the rocket for its debut flight. With weather looking favorable, the Vulcan rocket is on track to lift off at 2: 18 am ET (7: 18 UTC) on Monday from Cape Canaveral Space Force Station in Florida. The mission’s primary payload is a lunar lander built by Astrobotic, and the launch will be streamed live here.

This marks an absolutely pivotal moment for the 20-year-old launch company, which has gone from the titan of the US launch industry to playing a distant second fiddle to its one-time upstart competitor SpaceX. Last year, SpaceX launched 98 rockets. United Launch Alliance, or ULA, tallied just three. The owners of ULA, Lockheed Martin and Boeing, are also on the cusp of selling the launch company if they can find a buyer willing to pay the right price. And critically, for the first time, ULA will be flying a new vehicle it designed and developed on its own—a rocket with some but not a majority of its heritage from the legacy Atlas and Delta rockets that have flown since the Cold War.

So yeah, it’s a moment.

A little history

A quarter of a century ago, two of America’s largest aerospace contractors, Lockheed and Boeing, were the national leaders in providing launch services for the US military and many of NASA’s science missions. But they struggled to capture commercial satellite launches in an emerging market. Lockheed, with its Atlas rockets, and Boeing, with its Deltas, could not compete with Europe-based Arianespace and Russia on price. So the two US contractors doubled down on their competition for US government launch contracts.

The competition grew ugly, with allegations that Boeing stole rocket designs from Lockheed. The US Department of Justice began investigating how Boeing acquired tens of thousands of pages of trade secrets belonging to Lockheed Martin. There were lawsuits, and then questions about whether Boeing’s rocket business was viable. Military officials began to worry that if Boeing stopped flying the Delta, their only pathway into space would be through a Russian engine—the RD-180 that powered Lockheed’s Atlas V.

To ensure it had redundant access to space on two different rocket families, the military stepped in and arranged a shotgun marriage. The Department of Defense brokered a deal in which Lockheed and Boeing would merge their rocket-building ventures into one company, United Launch Alliance, in 2005. The parents retained a 50 percent ownership stake, and to sweeten the pot, the military agreed to pay a subsidy of about $1 billion a year.

Everything seemed to be working out well until SpaceX started launching rockets.

A little rivalry

ULA had tried to kill the baby. When SpaceX sought a launch site for its Falcon 9 rocket at Cape Canaveral in 2007, the parents lobbied the Air Force brass hard to stop the lease of Space Launch Complex-40 to Elon Musk and his rocket company. But the commander of the 45th Space Wing with oversight of Cape Canaveral, Gen. Susan Helms, approved the lease anyway.

Since then, ULA and SpaceX have been uneasy bedfellows in Florida, working side by side at nearby launch pads. Some of the rivalry was good-natured. Every week, for a while, engineers from SpaceX and ULA would meet up at Hogan’s Irish Bar in Cape Canaveral for trivia night. They would vie for nerd supremacy, drinking Guinness and blowing off steam.

But there have been more difficult confrontations. Musk kept pointing out the $1 billion subsidy at Congressional hearings—ULA officials bristled at the characterization of this ELC payment as a subsidy, but in effect, that’s what it was—and arguing that SpaceX’s Falcon 9 rocket could fly many of the military’s missions for much-reduced prices.

The issue came to a head in 2014, when the Air Force and ULA announced a new agreement for 36 national security launches to be flown during the remainder of the decade. ULA’s chief executive at the time, Mike Gass, hailed this “block buy” agreement because it would save the government $4.4 billion. Musk seethed. By then, his Falcon 9 rocket had launched eight times, all successfully. He sued the US government to stop the block buy and open up competition for the Falcon 9.

Several months into the lawsuit, SpaceX and the Air Force entered mediation. As part of the settlement, the military agreed to accelerate the certification of the Falcon 9 rocket and open up a number of the block buy launches to competition. SpaceX launched its first national security payload in 2017. SpaceX has not really looked back since.

Jeff Bezos (right), the founder of Blue Origin and Amazon.com, and Tory Bruno, CEO of United Launch Alliance, display a small-scale version of the BE-4 rocket engine during a press conference in 2014.

Enlarge / Jeff Bezos (right), the founder of Blue Origin and Amazon.com, and Tory Bruno, CEO of United Launch Alliance, display a small-scale version of the BE-4 rocket engine during a press conference in 2014.

As Vulcan nears debut, it’s not clear whether ULA will live long and prosper Read More »

a-week-with-a-ford-f-150-lightning:-this-truck-is-too-big-for-city-life

A week with a Ford F-150 Lightning: This truck is too big for city life

stalking horse or white elephant? —

The big electric pickup truck is out of the suburbs and out of its element.

A week with a Ford F-150 Lightning: This truck is too big for city life

Jonathan Gitlin

I seem to be thinking a lot about Ford’s electric pickup truck, the F-150 Lightning. Earlier this week, we got the news of price cuts and price increases. Before that, there was a pending cut to planned production output. Taken as it is, it’s just the all-electric version of America’s favorite pickup—and arguably the best version unless you need to pull something on the end of a trailer hitch.

But the Lightning doesn’t exist in a vacuum. Depending on who you talk to, it’s a clever attempt to get Americans to go electric, an utterly familiar wrapper on a slab of new technology that, yes, still requires the owner to adjust their mindset a bit from the gasoline-powered way of thinking. To others, it’s a white elephant, one that costs too much and languishes on dealership forecourts, proof positive that electrification is a thing other countries might bother with, but forget that here at home, cowboy.

I’ve never found life to be quite that simple, and neither is the Lightning. Here in Washington, DC, the vehicle remains a rare sight—the only time I’ve seen one in the wild, it belonged to the DC government’s fleet of vehicles (its job was inspecting abandoned vehicles). Out west, it’s much more common to see electric F-150s on the road, and last year, Ford sold about 40,000 Lightnings, despite halting production for a fire and then again to retool part of the line.

Because I last drove one more than 18 months ago, it seemed prudent to book a week with an example from Ford’s press fleet to see how the pickup has matured since its release. The Monroney sticker did little to bust the idea that these things are expensive—$97,374 is a high price, although with the recent adjustment and an ongoing $7,500 incentive from Ford, a 2024 model would be just over $10,000 cheaper, according to Ford’s online configurator.

Jonathan Gitlin

I had bigger concerns than the sticker shock—quite literally. After all, you don’t have to buy a Platinum trim Lightning; a search on cars.com shows 823 Platinums for sale around the country out of a total of 7,531 new Lightnings. Many of the rest of those electric F-150s will be cheaper, but all of them will be the same size. And that size is just too darn big for my life in the city.

Size matters

This was immediately apparent as I backed into my parking space. The Lightning dwarfed my neighbors’ SUVs as it jutted out into the parking lot, almost entirely filling the space between the white lines. There’s no hiding a vehicle that’s 237 inches (6,020 mm) long and 80 inches (2,032 mm) wide before you include the mirrors.

Part of the reason it’s so big is that the four-door, five-seat pickup truck somehow became the replacement for a sedan in the minds of so many American men. On four wheels, with at least eight inches of ground clearance, you could drive it on an overlanding adventure, but in practice, you’ll just obstruct the views of everyone else on the road. The only way to see around a big truck is in another big truck, and before you know it, the country is buying several million full-size pickup trucks every year.

I'll be honest: I used neither bed nor frunk during the entire week. Groceries and cargo went on the back seat or the floor behind the driver's seat. Which made most of the F-150 Lightning's bulk superfluous to my needs.

Enlarge / I’ll be honest: I used neither bed nor frunk during the entire week. Groceries and cargo went on the back seat or the floor behind the driver’s seat. Which made most of the F-150 Lightning’s bulk superfluous to my needs.

Jonathan Gitlin

For people living in newer homes in suburbs or exurbs who commute to jobs in office parks surrounded by vast expanses of surface parking, the size thing might not even be that noticeable. Garages are built big enough to house brodozers now, and houses out in those parts are set back from their neighbors. Climb up into the driver’s seat of a Lightning in the middle of a dense city, though, and it’s on stark display.

Although I adapted to the Lightning’s size, it was really only once I ventured into the suburbs of Northern Virginia that I started to feel truly comfortable behind the wheel. The multilane roads in places like Fairfax and Tysons Corner were much more the Lightning’s element. No road diets here, nor people on bicycles to be ever-vigilant for. Driving in the city, I was always aware of its size, although the view from the high-up driving position was mostly excellent, and the one-pedal driving mode made it simple to stick to the 20 mph speed limits.

A week with a Ford F-150 Lightning: This truck is too big for city life Read More »

daily-telescope:-a-crab-found-in-the-night-sky-rather-than-the-world’s-oceans

Daily Telescope: A crab found in the night sky rather than the world’s oceans

Krabby Patty —

Oh, to have seen this supernova back in the day.

The Crab Nebula in all its glory.

Enlarge / The Crab Nebula in all its glory.

Paul Macklin

Welcome to the Daily Telescope. There is a little too much darkness in this world and not enough light, a little too much pseudoscience and not enough science. We’ll let other publications offer you a daily horoscope. At Ars Technica, we’re going to take a different route, finding inspiration from very real images of a universe that is filled with stars and wonder.

Good morning. It’s January 5, and today’s photo reveals the Crab Nebula in all of its glory.

This object, known more formally as Messier 1 or M1, earned its colloquial name when Anglo-Irish astronomer William Parsons observed and drew this object in the early 1840s. It looked something like a crab with arms, and the appellation stuck. The nebula had been discovered about a century earlier by English astronomer John Bevis.

The nebula is actually a supernova remnant from a star that was observed popping in 1054 and recorded by Chinese astronomers. That must have been quite a sight, because the supernova occurred only about 2,000 light-years from Earth, which is relatively close as these things go. It likely was as bright as Venus and visible during daylight hours for a few weeks.

This image was captured by amateur astronomer Paul Macklin in Indiana. And it’s quite spectacular.

Source: Paul Macklin

Do you want to submit a photo for the Daily Telescope? Reach out and say hello.

Daily Telescope: A crab found in the night sky rather than the world’s oceans Read More »

rocket-report:-spacex’s-record-year;-firefly’s-alpha-rocket-falls-short

Rocket Report: SpaceX’s record year; Firefly’s Alpha rocket falls short

Ending big —

Living downrange from one of China’s launch sites sure doesn’t seem safe.

Firefly Aerospace's fourth Alpha rocket lifted off December 22 from Vandenberg Space Force Base, California.

Enlarge / Firefly Aerospace’s fourth Alpha rocket lifted off December 22 from Vandenberg Space Force Base, California.

Welcome to Edition 6.25 of the Rocket Report! We hope all our readers had a peaceful holiday break. While many of us were enjoying time off work, launch companies like SpaceX kept up the pace until the final days of 2023. Last year saw a record level of global launch activity, with 223 orbital launch attempts and 212 rockets successfully reaching orbit. Nearly half of these missions were by SpaceX.

As always, we welcome reader submissions, and if you don’t want to miss an issue, please subscribe using the box below (the form will not appear on AMP-enabled versions of the site). Each report will include information on small-, medium-, and heavy-lift rockets, as well as a quick look ahead at the next three launches on the calendar.

Firefly’s fourth launch puts payload in wrong orbit. The fourth flight of Firefly Aerospace’s Alpha rocket on December 22 placed a small Lockheed Martin technology demonstration satellite into a lower-than-planned orbit after lifting off from Vandenberg Space Force Base, California. US military tracking data indicated the Alpha rocket released its payload into an elliptical orbit ranging between 215 and 523 kilometers in altitude, not the mission’s intended circular target orbit. Firefly later confirmed the Alpha rocket’s second stage, which was supposed to reignite about 50 minutes after liftoff, did not deliver Lockheed Martin’s satellite into the proper orbit. This satellite, nicknamed Tantrum, was designed to test Lockheed Martin’s new wideband Electronically Steerable Antenna technology to demonstrate faster on-orbit sensor calibration to deliver rapid capabilities to US military forces.

Throwing a tantrum? … This was the third time in four flights that Firefly’s commercial Alpha rocket, designed to loft payloads up to a metric ton in mass, has not reached its orbital target. The first test flight in 2021 suffered an engine failure on the first stage before losing control shortly after liftoff. The second Alpha launch in 2022 deployed its satellites into a lower-than-planned orbit, leaving them unable to complete their missions. In September, Firefly launched a small US military satellite on a responsive launch demonstration. Firefly and the US Space Force declared that mission fully successful. Atmospheric drag will likely pull Lockheed Martin’s payload back into Earth’s atmosphere for a destructive reentry in a matter of weeks. The good news is ground teams are in contact with the satellite, so there could be a chance to complete at least some of the mission’s objectives. (submitted by Ken the Bin)

Australian startup nears first launch. The first locally made rocket to be launched into space from Australian soil is scheduled for liftoff from a commercial facility in Queensland early next year, the Australian Broadcasting Corporation reports. A company named Gilmour Space says it hopes to launch its first orbital-class Eris rocket in March, pending final approval from Australian regulatory authorities. This would be the first Australian-built orbital rocket, although a US-made rocket launched Australia’s first satellite from a military base in South Australia in 1967. The UK’s Black Arrow rocket also launched a satellite from the same remote Australian military base in 1971.

Getting to know Eris … The three-stage Eris rocket stands 25 meters (82 feet) tall with the ability to deliver up to 300 kilograms (660 pounds) of payload into low-Earth orbit, according to Gilmour Space. The company says the Eris rocket will be powered by Gilmour’s “new and proprietary hybrid rocket engine.” These kinds of propulsion systems use a solid fuel and a liquid oxidizer. We’ll be watching to see if Gilmour shares more tangible news about the progress toward the first Eris launch in March. In late 2022, the company targeted April 2023 for the first Eris flight, so this program has a history of delays. (submitted by Marzipan and Onychomys)

The easiest way to keep up with Eric Berger’s space reporting is to sign up for his newsletter, we’ll collect his stories in your inbox.

A commander’s lament on the loss of a historic SpaceX booster. The Falcon 9 rocket that launched NASA astronauts Doug Hurley and Bob Behnken on SpaceX’s first crew mission in 2020 launched and landed for the 19th and final time just before Christmas, then tipped over on its recovery ship during the trip back to Cape Canaveral, Florida, Ars reports. This particular booster, known by the tail number B1058, was special among SpaceX’s fleet of reusable rockets. It was the fleet leader, having tallied 19 missions over the course of more than three-and-a-half years. More importantly, it was the rocket that thundered into space on May 30, 2020, on a flight that made history.

A museum piece? … The lower third of the booster was still on the deck of SpaceX’s recovery ship as it sailed into Port Canaveral on December 26. This portion of the rocket contains the nine Merlin engines and landing legs, some of which appeared mangled after the booster tipped over in high winds and waves. Hurley, who commanded SpaceX’s Crew Dragon spacecraft on the booster’s historic first flight in 2020, said he hopes to see the remaining parts of the rocket in a museum. “Hopefully they can do something because this is a little bit of an inauspicious way to end its flying career, with half of it down at the bottom of the Atlantic Ocean,” said Hurley.

SpaceX opens 2024 campaign with a new kind of Starlink satellite. SpaceX has launched the first six Starlink satellites that will provide cellular transmissions for customers of T-Mobile and other carriers, Ars reports. A Falcon 9 rocket launched from California on January 2 carried 21 Starlink satellites overall, including the first six Starlinks with Direct to Cell capabilities. SpaceX says these satellites, and thousands of others to follow, will “enable mobile network operators around the world to provide seamless global access to texting, calling, and browsing wherever you may be on land, lakes, or coastal waters without changing hardware or firmware.” T-Mobile said that field testing of Starlink satellites with the T-Mobile network will begin soon. “The enhanced Starlink satellites have an advanced modem that acts as a cellphone tower in space, eliminating dead zones with network integration similar to a standard roaming partner,” SpaceX said.

Two of 144 … SpaceX followed this launch with another Falcon 9 flight from Florida on January 3 carrying a Swedish telecommunications satellite. These were the company’s first two missions of 2024, a year when SpaceX officials aim to launch up to 144 rockets, an average of 12 per month, exceeding the 98 rockets it launched in 2023. A big focus of SpaceX’s 2024 launch manifest will be delivering these Starlink Direct to Cell satellites into orbit. (submitted by Ken the Bin)

Chinese booster lands near homes. China added a new pair of satellites to its Beidou positioning and navigation system on December 25, but spent stages from the launch landed within inhabited areas, Space News reports. Meanwhile, a pair of the side boosters from the Long March 3B rocket used for the launch appeared to fall to the ground near inhabited areas in Guangxi region, downrange of the Xichang spaceport in Sichuan province, according to apparent bystander footage on Chinese social media. One video shows a booster falling within a forested area and exploding, while another shows a falling booster and later, wreckage next to a home.

Life downrange … Chinese government authorities reportedly issue warnings and evacuation notices for citizens living in regions where spent rocket boosters are likely to fall after launch, but these videos clearly show people are still close by as the rockets fall from the sky. We’ve seen this kind of imagery before, including views of a rocket that crashed into a rural building in 2019. What’s more, the rockets return to Earth with leftover toxic propellants—hydrazine and nitrogen tetroxide—that could be deadly to breathe or touch. Clouds of brownish-orange gas are visible around the rocket wreckage, an indication of the presence of nitrogen tetroxide. China built its three Cold War-era spaceports in interior regions to protect them from possible military attacks, while its newest launch site is at a coastal location on Hainan Island, allowing rockets launched there to drop boosters into the sea. (submitted by Ken the Bin and EllPeaTea)

Launch date set for next H3 test flight. The second flight of Japan’s new flagship H3 rocket is scheduled for February 14 (US time; February 15 in Japan), the Japan Aerospace Exploration Agency announced on December 28. This will come nearly one year after the first H3 test flight failed to reach orbit last March when the rocket’s second stage failed to ignite a few minutes after liftoff. This failure destroyed a pricey Japanese Earth observation satellite and dealt a setback to Japan’s rocket program. The H3 is designed to be cheaper and more capable than the H-IIA and H-IIB rockets it will replace. Eventually, the H3 will launch Japan’s scientific research probes, spy satellites, and commercial payloads.

Fixes since the first flight … Engineers narrowed the likely cause for the first H3 launch failure to an electrical issue, although Japanese officials have not provided an update on the investigation for several months. In August, Japan’s space agency said investigators had narrowed the cause of the H3’s second-stage malfunction to three possible failure scenarios. Nevertheless, officials are apparently satisfied the H3 is ready to fly again. But this time, there won’t be an expensive satellite aboard. A dummy payload will fly inside the H3 rocket’s nose cone, along with two relatively low-cost small satellites hitching a piggyback ride to orbit. (submitted by Ken the Bin and EllPeaTea)

India’s PSLV launches first space mission of 2024. The first orbital launch of the new year, as measured in the globally recognized Coordinated Universal Time, or UTC, was the flight of an Indian Polar Satellite Launch Vehicle (PSLV) on January 1 (December 31 in the United States). This launch deployed an X-ray astronomy satellite named XPoSat, which will measure X-ray emissions from black holes, neutron stars, active galactic nuclei, and pulsars. This is India’s first X-ray astronomy satellite, and its launch is another sign of India’s ascendence among the world’s space powers. India has some of the world’s most reliable launch vehicles, is developing a human-rated capsule to carry astronauts into orbit, and landed its first robotic mission on the Moon last year.

Going lower … After releasing the XPoSat payload, the PSLV’s fourth stage lowered its orbit to begin an extended mission hosting 10 scientific and technology demonstration experiments. These payloads will test new radiation shielding technologies, green propulsion, and fuel cells in orbit, according to the Indian Space Research Organization. On missions with excess payload capacity, India has started offering researchers and commercial companies the opportunity to fly experiments on the PSLV fourth stage, which has its own solar power source to essentially turn itself from a rocket into a satellite platform. (submitted by EllPeaTea and Ken the Bin)

Mixed crews will continue flying to the International Space Station. NASA and the Russian space agency, Roscosmos, will extend an agreement on flying each other’s crew members to the International Space Station through 2025, Interfax reports. This means SpaceX’s Crew Dragon spacecraft and Boeing’s Starliner capsule, once operational, will continue transporting Russian cosmonauts to and from the space station, as several recent SpaceX crew missions have done. In exchange, Russia will continue flying US astronauts on Soyuz missions.

There’s a good reason for this… Despite poor relations on Earth, the US and Russian governments continue to be partners on the ISS. While NASA no longer has to pay for seats on Soyuz spacecraft, the US space agency still wants to fly its astronauts on Soyuz to protect against the potential for a failure or lengthy delay with a SpaceX or Boeing crew mission. Such an event could lead to a situation where the space station has no US astronauts aboard. Likewise, Roscosmos benefits from this arrangement to ensure there’s always a Russian on the space station, even in the event of a problem with Soyuz. (submitted by Ken the Bin)

SpaceX sets new records to close out 2023. SpaceX launched two rockets, three hours apart, to wrap up a record-setting 2023 launch campaign, Ars reports. On December 28, SpaceX launched a Falcon Heavy rocket from NASA’s Kennedy Space Center in Florida with the US military’s super-secret X-37B spaceplane. Less than three hours later, a Falcon 9 rocket took off a few miles to the south with another batch of Starlink Internet satellites. These were SpaceX’s final launches of 2023. SpaceX ended the year with 98 flights, including 91 Falcon 9s, five Falcon Heavy rockets, and two test launches of the giant new Super Heavy-Starship rocket. These flights were spread across four launch pads in Florida, California, and Texas. It was also the shortest turnaround between two SpaceX flights in the company’s history, and set a modern-era record at Cape Canaveral, Florida, with the shortest span between two orbital-class launches there since 1966.

Where’s the X-37B?… The military’s reusable X-37B spaceplane that launched on the Falcon Heavy rocket apparently headed into an unusually high orbit, much higher than the spaceplane program’s previous six flights. But the military kept the exact orbit a secret, and amateur skywatchers will be closely watching for signs of the spaceplane passing overhead in hopes of estimating its apogee, perigee, and inclination. What the spaceplane is doing is also largely a mystery. The X-37B resembles a miniature version of NASA’s retired space shuttle orbiter, with wings, deployable landing gear, and black thermal protection tiles to shield its belly from the scorching heat of reentry.

Elon Musk says SpaceX needs to built a lot of Starships. Even with reusability, SpaceX will need to build Starships as often as Boeing builds 737 jetliners in order to realize Elon Musk’s ambition for a Mars settlement, Ars reports. “To achieve Mars colonization in roughly three decades, we need ship production to be 100/year, but ideally rising to 300/year,” Musk wrote on his social media platform X. SpaceX still aims to make the Starship and its Super Heavy booster rapidly reusable. The crux is that the ship, the part that would travel into orbit, and eventually to the Moon or Mars, won’t be reused as often as the booster. These ships will come in a number of different configurations, including crew and cargo transports, refueling ships, fuel depots, and satellite deployers.

Laws of physics… The first stage of the giant launch vehicle, named Super Heavy, is designed to return to SpaceX’s launch sites about six minutes after liftoff, similar to the way SpaceX recovers its Falcon boosters today. Theoretically, Musk wrote, the booster could be ready for another flight in an hour. With the Starship itself, the laws of physics and the realities of geography come into play. As an object flies in low-Earth orbit, the Earth rotates underneath it. This means that a satellite, or Starship, will find itself offset some 22.5 degrees in longitude from its launch site after a single 90-minute orbit around the planet. It could take several hours, or up to a day, for a Starship in low-Earth orbit to line up with one of the recovery sites. “The ship needs to complete at least one orbit, but often several to have the ground track line back up with the launch site, so reuse may only be daily,” Musk wrote. “This means that ship production needs to be roughly an order of magnitude higher than booster production.”

Next three launches

January 5: Kuaizhou 1A | Unknown Payload | Jiuquan Satellite Launch Center, China | 11: 20 UTC

January 7:  Falcon 9 | Starlink 6-35 | Cape Canaveral Space Force Station, Florida | 21: 00 UTC

January 8: Falcon 9 | Starlink 7-10 | Vandenberg Space Force Base, California | 05: 00 UTC

Rocket Report: SpaceX’s record year; Firefly’s Alpha rocket falls short Read More »

elon-musk:-spacex-needs-to-build-starships-as-often-as-boeing-builds-737s

Elon Musk: SpaceX needs to build Starships as often as Boeing builds 737s

Ship 28, the Starship for SpaceX's next full-scale test flight, fires up one of its engines on December 29 in Texas.

Enlarge / Ship 28, the Starship for SpaceX’s next full-scale test flight, fires up one of its engines on December 29 in Texas.

SpaceX

It’s no secret that Elon Musk has big ambitions for SpaceX’s Starship mega-rocket. This is the vehicle that, with plenty of permutations and upgrades, Musk says will ferry cargo and people across the Solar System to build a settlement on Mars, making humanity a multi-planetary species and achieving the billionaire’s long-standing dream.

Of course, that is a long way off. SpaceX is still working on getting Starship into orbit or close to it, an achievement that appears to be possible this year. Then, the company will start launching Starlink satellites on Starship missions while testing in-space refueling technology needed to turn Starship into a human-rated Moon lander for NASA.

SpaceX’s South Texas team is progressing toward the third full-scale Starship test flight. On December 20, the Starship’s upper stage slated for the next test flight completed a test-firing of its Raptor engines at the Starbase launch site on the Texas Gulf Coast. Nine days later, the 33-engine Super Heavy booster fired up on the launch pad for its own static fire test. On the same day, SpaceX hot-fired the Starship upper stage once again on a test stand next to the launch pad.

With those milestones complete, ground teams rolled the booster back to its hangar for final preflight checks and reconfigurations. The ship, too, will need to be rolled back to its high bay.

SpaceX could be weeks away from having both vehicles ready to fly, but the company hasn’t released an update on lessons learned from the previous Starship test flight in November. That flight was largely successful, with apparently flawless performance from the 33 engines on the Super Heavy booster during launch. The Starship upper stage reached space before self-destructing downrange over the Gulf of Mexico. The booster exploded during a maneuver to bring itself back to Earth for a controlled splashdown at sea.

The company’s engineers will want to understand and correct whatever caused those issues. The Federal Aviation Administration then needs to approve SpaceX’s investigation into the last Starship flight before issuing a new commercial launch license. When it flies again, Starship will try to reach near orbital velocity, enough speed to travel most of the way around the world before reentering the atmosphere near Hawaii.

Verifying the performance of Starship’s heat shield tiles during reentry will be valuable learning for SpaceX, but Starship first needs to be fully successful with a launch. This is just the start for the privately funded Starship program.

Elon Musk: SpaceX needs to build Starships as often as Boeing builds 737s Read More »